阅读说明：本技术 用于运动障碍的治疗药物 (Therapeutic agent for dyskinesia ) 是由 栗田光将 池田友纪 中塔充宏 于 2020-04-24 设计创作，主要内容包括：本发明提供了可用于帕金森病中左旋多巴诱导的运动障碍的治疗药物。具体地,本发明提供了用于治疗、改善、阻滞或预防与帕金森病的左旋多巴疗法有关的运动并发症、特别是左旋多巴诱导的运动障碍(PD-LID)的组合物和方法,其包含坦度螺酮或其药学上可接受的盐或前药,其中胃肠外地施用坦度螺酮或其药学上可接受的盐或前药。(The present invention provides a therapeutic drug useful for levodopa-induced dyskinesia in parkinson's disease. In particular, the present invention provides compositions and methods for treating, ameliorating, blocking or preventing motor complications associated with levodopa therapy of parkinson's disease, in particular levodopa-induced dyskinesia (PD-LID), comprising tandospirone or a pharmaceutically acceptable salt or prodrug thereof, wherein the tandospirone or pharmaceutically acceptable salt or prodrug thereof is administered parenterally.)